AR127705A1 - Heterociclos inhibidores de nlrp3 - Google Patents
Heterociclos inhibidores de nlrp3Info
- Publication number
- AR127705A1 AR127705A1 ARP220103167A ARP220103167A AR127705A1 AR 127705 A1 AR127705 A1 AR 127705A1 AR P220103167 A ARP220103167 A AR P220103167A AR P220103167 A ARP220103167 A AR P220103167A AR 127705 A1 AR127705 A1 AR 127705A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- substituted
- disease
- disorder
- condition
- Prior art date
Links
- 102000000874 Pyrin Domain-Containing 3 Protein NLR Family Human genes 0.000 title abstract 3
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 8
- 238000000034 method Methods 0.000 abstract 6
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 4
- 208000035475 disorder Diseases 0.000 abstract 4
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 125000005842 heteroatom Chemical group 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 101100222017 Candida albicans (strain SC5314 / ATCC MYA-2876) CSA2 gene Proteins 0.000 abstract 2
- 101100519698 Candida albicans (strain SC5314 / ATCC MYA-2876) PGA10 gene Proteins 0.000 abstract 2
- 102100026280 Cryptochrome-2 Human genes 0.000 abstract 2
- 101000855613 Homo sapiens Cryptochrome-2 Proteins 0.000 abstract 2
- 125000001188 haloalkyl group Chemical group 0.000 abstract 2
- 238000011321 prophylaxis Methods 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- -1 1,2,3,5,6,7,8,8a-octahydroindolizine-7- yl Chemical group 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 101150011071 CRZ1 gene Proteins 0.000 abstract 1
- 101100275810 Candida albicans (strain SC5314 / ATCC MYA-2876) CRZ2 gene Proteins 0.000 abstract 1
- 102100029376 Cryptochrome-1 Human genes 0.000 abstract 1
- 101000919351 Homo sapiens Cryptochrome-1 Proteins 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 150000002825 nitriles Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21208773 | 2021-11-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR127705A1 true AR127705A1 (es) | 2024-02-21 |
Family
ID=78676487
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220103167A AR127705A1 (es) | 2021-11-17 | 2022-11-17 | Heterociclos inhibidores de nlrp3 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240409553A1 (OSRAM) |
| EP (1) | EP4433480A1 (OSRAM) |
| JP (1) | JP2024540445A (OSRAM) |
| CN (1) | CN118234730A (OSRAM) |
| AR (1) | AR127705A1 (OSRAM) |
| TW (1) | TW202334153A (OSRAM) |
| WO (1) | WO2023088856A1 (OSRAM) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| US20240391881A1 (en) * | 2021-09-30 | 2024-11-28 | Origiant Pharmaceutical Co., Ltd. | Pharmaceutical use and preparation method for substituted heteroaryl phthalazine derivative |
| US20260015357A1 (en) * | 2022-07-01 | 2026-01-15 | Neumora Therapeutics, Inc. | Modulators of nlrp3 inflammasome and related products and methods |
| CN116789674B (zh) * | 2022-08-24 | 2024-05-24 | 杭州高光制药有限公司 | Nlrp3炎性小体抑制剂 |
| US12331048B2 (en) | 2022-10-31 | 2025-06-17 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors |
| CN121045190A (zh) * | 2022-11-04 | 2025-12-02 | 药捷安康(南京)科技股份有限公司 | Nlrp3炎症小体抑制剂及其应用 |
| EP4644392A1 (en) * | 2022-12-27 | 2025-11-05 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Pyridazine fused aryl ring compound and use thereof |
| WO2025026252A1 (en) * | 2023-08-02 | 2025-02-06 | Hangzhou Highlightll Pharmaceutical Co., Ltd | Nlrp3 inflammasome inhibitors |
| WO2025133307A1 (en) * | 2023-12-22 | 2025-06-26 | Ac Immune Sa | Heterocyclic modulators of the nlrp3 inflammasome pathway |
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
| WO2025153624A1 (en) * | 2024-01-17 | 2025-07-24 | Ac Immune Sa | Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway |
| WO2025153625A1 (en) * | 2024-01-17 | 2025-07-24 | Ac Immune Sa | Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway |
| WO2026057747A1 (en) | 2024-09-11 | 2026-03-19 | Ac Immune Sa | Therapeutic use of nlrp3 inflammasome pathway inhibitor compounds |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2868780B1 (fr) * | 2004-04-13 | 2008-10-17 | Sanofi Synthelabo | Derives de la 1-amino-phthalazine, leur preparation et leur application en therapeutique |
| WO2018221433A1 (ja) * | 2017-05-29 | 2018-12-06 | 第一三共株式会社 | ヘテロアリールアミン誘導体 |
| UY38687A (es) * | 2019-05-17 | 2023-05-15 | Novartis Ag | Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso |
| JP7843705B2 (ja) | 2020-01-22 | 2026-04-10 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | Ｎｌｒｐ３モジュレーターとしてのスルホンイミドアミド化合物 |
| US20240327413A1 (en) | 2021-06-29 | 2024-10-03 | Zomagen Biosciences Ltd | Nlrp3 modulators |
| TW202319055A (zh) | 2021-07-21 | 2023-05-16 | 日商安斯泰來製藥股份有限公司 | 縮環噠嗪（ｐｙｒｉｄａｚｉｎｅ）化合物 |
| PE20241727A1 (es) | 2021-08-25 | 2024-08-19 | Ptc Therapeutics Inc | Inhibidores de nlrp3 |
| US20240391881A1 (en) | 2021-09-30 | 2024-11-28 | Origiant Pharmaceutical Co., Ltd. | Pharmaceutical use and preparation method for substituted heteroaryl phthalazine derivative |
| WO2023066377A1 (zh) | 2021-10-22 | 2023-04-27 | 索智生物科技（浙江）有限公司 | 一种含氮化合物、其制备方法及应用 |
-
2022
- 2022-11-15 EP EP22818255.6A patent/EP4433480A1/en active Pending
- 2022-11-15 JP JP2024528510A patent/JP2024540445A/ja active Pending
- 2022-11-15 CN CN202280075550.2A patent/CN118234730A/zh active Pending
- 2022-11-15 WO PCT/EP2022/081866 patent/WO2023088856A1/en not_active Ceased
- 2022-11-16 TW TW111143745A patent/TW202334153A/zh unknown
- 2022-11-17 AR ARP220103167A patent/AR127705A1/es unknown
-
2024
- 2024-05-15 US US18/665,390 patent/US20240409553A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN118234730A (zh) | 2024-06-21 |
| JP2024540445A (ja) | 2024-10-31 |
| EP4433480A1 (en) | 2024-09-25 |
| TW202334153A (zh) | 2023-09-01 |
| WO2023088856A1 (en) | 2023-05-25 |
| US20240409553A1 (en) | 2024-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR127704A1 (es) | Derivados de piridazina inhibidores de nlrp3 | |
| CO2017009891A2 (es) | Inhibidores de inhibidores del factor beta de crecimiento de transformación (tgf-beta) | |
| AR115822A1 (es) | Compuestos de sulfonimidamida como inhibidores de la actividad de interleuquina-1 | |
| UY37795A (es) | Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3 | |
| AR100049A1 (es) | Derivados de dihidrotiazina y dihidrooxazina con actividad inhibidora de bace1 | |
| EA201691401A1 (ru) | Индазольные соединения в качестве ингибиторов irak4 | |
| AR105893A1 (es) | Derivados del anillo (hetero) aromático sustituidos con carboxi como inhibidores de xantina oxidasa y del transportador 1 del anión urato | |
| DOP2019000140A (es) | Compuestos de heterociclo tetracíclicos útiles como inhibidores de la integrasa del vih | |
| JOP20190115A1 (ar) | مثبّطات إنزيم بولي (adp-ريبوز) بوليمراز (parp) | |
| CU20160097A7 (es) | Compuestos de imidazopirazina como inhibidores de syk | |
| EA201692418A1 (ru) | Замещенные индазольные соединения в качестве irak4 ингибиторов | |
| UY35617A (es) | Inhibidores de la fosfatidilinositol 3-quinasa | |
| CR20210213A (es) | Derivados de quinolina como inhibidores de la integrina alfa4beta7 | |
| CR20190504A (es) | COMPUESTO DE AMIDA (Divisional 2015-0454) | |
| MA38922A2 (fr) | Dérivés de quinolizine substitués utiles en tant qu'inhibiteurs de l'integrase du vih | |
| NZ726608A (en) | Phosphatidylinositol 3-kinase inhibitors | |
| NZ726055A (en) | Quinazolinone derivatives as phosphatidylinositol 3-kinase inhibitors | |
| NZ726360A (en) | Phosphatidylinositol 3-kinase inhibitors | |
| MX2020011317A (es) | Compuestos heterociclicos triciclicos utiles como inhibidores de la integrasa de vih. | |
| PE20200445A1 (es) | Inhibidores pirazolicos de magl | |
| AR115965A1 (es) | Derivados heteroaromáticos de carboxamida como inhibidores de la calicreína plasmática | |
| AR124868A1 (es) | Compuestos de heterociclo tetracíclicos útiles como inhibidores de la integrasa del vih | |
| AR110349A1 (es) | Compuestos pirazol 1,3-sustituido útiles para la reducción de los niveles de ácidos grasos de cadena muy larga | |
| EA201890361A1 (ru) | Производные 5-(n-бензил-тетрагидроизохинолин-6-ил)пиридин-3-ил-уксусной кислоты в качестве ингибиторов репликации вируса иммунодефицита человека | |
| MX389378B (es) | Derivados de amino-imidazopiridina novedosos como inhibidores de cinasa de janus y uso farmacéutico de estos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |